Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 273

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Open access
Qin, Haiying, Ramakrishna, Sneha, Nguyen, Sang, Fountaine, Thomas J., Ponduri, Anusha, Stetler-Stevenson, Maryalice, Yuan, Constance M., Haso, Waleed, Shern, Jack F., Shah, Nirali N., Fry, Terry J.·2018·Molecular Therapy - Oncolytics

Abstract

Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained remission rates. A systematic approach to the generation of CAR constructs incorporating two target-binding domains led to several novel CD19/CD22 bivalent CAR constructs. Importantly, we demonstrate the challenges associated with the construction of a bivalent CAR format that preserves bifunctionality against both CD19 and CD22. Using the most active bivalent CAR constructs, we found similar transduction efficiency compared to that of either CD19 or CD22 single CARs alone. When expressed on human T cells, the optimized CD19/CD22 CAR construct induced comparable interferon γ and interleukin-2 in vitro compared to single CARs against dual-antigen-expressing as well as single-antigen-expressing cell lines. Finally, the T cells expressing CD19/CD22 CAR eradicated ALL cell line xenografts and patient-derived xenografts (PDX), including a PDX generated from a patient with CD19 − relapse following CD19-directed CAR therapy. The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce risk of antigen loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omto.2018.10.006

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 273

Metadata

Authors
Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., Yuan, C. M., Haso, W., Shern, J. F., Shah, N. N., & Fry, T. J.
Venue
Molecular Therapy - Oncolytics
Publisher
Elsevier BV
Published
2018-12
Volume
11
Pages
127-137
ISSN
2372-7705 (ISSN-L)
OpenAlex
W2899700403
Cited by
273
References
23
FWCI
10.03
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. https://app.cochat.ai/papers/10.1016/j.omto.2018.10.006
The paper
Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., Yuan, C. M., Haso, W., Shern, J. F., Shah, N. N., & Fry, T. J. (2018). Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. Molecular Therapy - Oncolytics. https://doi.org/10.1016/j.omto.2018.10.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.